Bluestone Jeffrey 4

What Happened
Jeffrey Bluestone, a director of Gilead Sciences, exercised stock options and sold shares on January 20, 2026. The filing shows an exercise of 5,000 option shares at $67.45 per share (cost $337,250) and an open-market sale of 5,000 shares at $123.50 per share (proceeds $617,500). The report also lists a separate 5,000-share derivative disposition with $0.00 consideration (the filing does not explain the reason for the $0.00 disposition). The activity involves both option exercise and a sale; sales are routine insider transactions but purchases (option exercises) can be viewed as acquiring stock.

Key Details

• Transaction date: 2026-01-20.
• Option exercise: 5,000 shares acquired at $67.45 each (total $337,250).
• Open-market sale: 5,000 shares sold at $123.50 each (total $617,500).
• Derivative disposition: 5,000 shares reported as disposed for $0.00 (no explanation in the filing).
• Footnotes: Transaction made pursuant to a Rule 10b5-1 trading plan adopted Feb 13, 2025; vesting schedule note for the option (25% vests every three months from May 12, 2021).
• Shares owned after the transactions: not disclosed in the provided data.
• Filing timeliness: no late filing indicated in the provided information.

Context

• The filing shows exercise(s) and a sale of the same number of shares on the same date, which often indicates exercised shares were sold the same day (commonly a cashless exercise/monetization), though the filing itself does not state the mechanics.
• The 10b5-1 plan note means the sale was executed under a pre-established trading plan (designed to avoid concerns about trading on non-public information).
• The $0.00 derivative disposition could reflect net settlement, tax withholding, or another administrative action, but the filing does not specify which.